Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial
Caixeta A, Stone GW, Mehran R, Lee EA, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Ohman EM, Palmerini T, Syros G, Kittas C, Fahy M, Hooper WC, Lansky AJ, Dangas GD. Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial. Journal Of Thrombosis And Thrombolysis 2010, 31: 154-164. PMID: 20953817, DOI: 10.1007/s11239-010-0516-y.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeC-reactive proteinTroponin-positive patientsBaseline CRP levelsCRP levelsACUITY trialCoronary syndromeHigh-risk acute coronary syndromesQuartiles of CRPEarly invasive treatment strategyRelationship of CRPHigher baseline CRP levelsEarly invasive strategyLong-term mortalityPowerful independent predictorEarly invasive treatmentTroponin-negative patientsInvasive treatment strategyLate mortalityPositive patientsIndependent predictorsClinical outcomesCRP valuesHighest quartileMultivariable analysisThe relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention.
Saltzman AJ, Mehran R, Hooper WC, Moses JW, Weisz G, Collins MB, Lansky AJ, Kreps EM, Leon MB, Stone GW, Dangas G. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention. Journal Of Invasive Cardiology 2010, 22: 2-6. PMID: 20048389.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngina, UnstableAngioplasty, Balloon, CoronaryAntibodies, MonoclonalBlood PlateletsC-Reactive ProteinDose-Response Relationship, DrugDouble-Blind MethodDrug Therapy, CombinationFemaleHeparinHumansImmunoglobulin Fab FragmentsMaleMiddle AgedPilot ProjectsPlatelet AggregationPlatelet Aggregation InhibitorsStentsTime FactorsTirofibanTyrosineConceptsPercutaneous coronary interventionC-reactive proteinTarget vessel revascularizationPlatelet inhibitionCoronary interventionLevels of CRPInflammatory markers C-reactive proteinPlatelet aggregationC-reactive protein levelsDouble-blind study designEfficacy of tirofibanLower platelet inhibitionCoronary artery bypassCoronary artery revascularizationArtery revascularizationDiabetic subsetEligible patientsNonfatal MIArtery bypassHs-CRPVessel revascularizationSpearman correlation coefficient modelClinical endpointsFirst time pointTirofiban